EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction

BACKGROUND: Erlotinib and gefitinib are weak base drugs whose absorption and clinical efficacy may be impaired by concomitant gastric acid suppressive (AS) therapy, yet proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2As) are widely indicated in non-small cell lung cancer (NSCLC...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Main Authors: Kumarakulasinghe, Nesaretnam Barr, Syn, Nicholas, Soon, Yu Yang, Asmat, Atasha, Zheng, Huili, Loy, En Yun, Pang, Brendan, Soo, Ross Andrew
Formato: Artigo
Idioma:Inglês
Publicado: Impact Journals LLC 2016
Assuntos:
Research Paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5356756/
https://ncbi.nlm.nih.gov/pubmed/27907909
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.13458
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares